Le centre médical Sheba à Tel HaShomer va collaborer avec le groupe suisse Lonza pour développer une thérapie génique pour guérir plus rapidement et plus économiquement la leucémie et les lymphomes.
L’hôpital a indiqué qu’elle se servira de la nouvelle plateforme Cocoon de Lonza pour produire des cellules CAR-T humaines génétiquement modifiées pour traiter les patients en oncologie. C’est la première fois que cette plateforme est utilisée par un hôpital, a souligné le professeur Dror Harats, vice-directeur de la recherche et développement pour les essais cliniques du centre médical Sheba dans une interview. (Times of Israel)
Lonza Group is a Swiss multinational, chemicals and biotechnology company, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including organic, fine and performance chemicals, custom manufacturing of biopharmaceuticals, chemical synthesis capabilities, detection systems and services for the bioscience sector.
Lonza was founded in 1897 in the small Swiss town of Gampel, situated in the canton of Valais, taking its name from the nearby river. Initially the company produced electricity used to manufacture chemicals such as calcium carbide. Lonza moved to neighbouring Visp (where it retains a production site today) in 1909 and began manufacturing synthetic fertilisers, and moves into vitamins, acids, intermediates and additives followed. In 1974, the group merged with aluminium firm Alusuisse, after which the group moved into the biotechnology sector. Lonza de-merged from the Alusuisse-Lonza Group in 1999 and listed on the SWX Swiss Exchange.
